Method for determining the primary structure AF217798 of the messenger RNA encoding human recombinant endo-oligopeptidase A (hEOPA) and its protein sequence AAF24516; Method for determining the human EOPA gene and method for producing human recombinant EOPA; Methods for the production of anti-EOPA antibodies; standardization and use of synthetic substrates for determining the biochemical and proteolytic properties of hEOPA; oligopeptides acting as EOPA catalytic activity or 'soluble receptors' and Methods for identifying and generating inhibitors and antibodies that exhibit inhibitory activity against the ability of EOPA to interact; methods for identifying this protein in congenital, infectious and degenerative conditions of the central nervous system, and immunological How to determine the role of EOPA in a process Immunochemical and / or enzymatic diagnostic methods used for diagnosis or treatment of congenital, infectious and / or degenerative diseases of the central nervous sy

摘要

This invention refers to the recombinant human endooligopeptidase (hEOPA), polynucleotide which codes for the hEOPA, polynucleotide which allow the expression of the EOPA in prokaryotes and eukaryotes, including the human beings; use of the synthetic substrates for the determination of the proteolytic activity of the hEOPA, or of its chaperon activity or its activity as soluble peptide receptor; obtaining and using of the specific antibodies and inhibitors of its oligopeptide binding activity, as agonists, competitors and antagonists, which are able to disturb its interaction and the complex formation with other proteins. The invention also refers to the application of the natural and recombinant protein, chemically or genetically modified which aim is the diagnosis and/or the application in congenital, infectious and degenerative pathologic conditions of the central nervous system, and for psychiatric and behavioral dysfunctions. It is also proposed the application of the inhibitors and competitors for the interaction of EOPA with ligands, including antibodies or their derivatives, for the treatment of tissular and neurodegenerative pathologies.